BELGRADE, Mont., April 23, 2025 /PRNewswire/ — Xtant Medical Holdings, Inc.(NYSE American:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic and woundcare disorders, is proud to announce the launch of Trivium™, a premium, next-generation demineralized bone matrix (DBM) allograft designed to elevate the standard of care in bone grafting procedures. Engineered with advanced PureLoc™ Fiber Technology, Trivium combines three synergistic elements intended to deliver exceptional performance in structure, handling, and biological activity.
Trivium is uniquely designed, featuring intertwined structures and interconnected porosity that support the attachment and proliferation of a variety of cell types, and designed to promote robust tissue ingrowth. This advanced composition creates an ideal environment for healing and regeneration.
With its superior moldability and handling characteristics, Trivium allows surgeons to place the graft with precision across a wide range of surgical applications.
Trivium is processed using Xtant’s proprietary BacteRinse® method, clinically proven over two decades to preserve native bone morphogenetic proteins (BMPs). This ensures Trivium delivers a complete suite of bioavailable growth factors critical to initiating and supporting bone repair.
“Trivium represents a significant advancement in bone grafting technology,” said Sean Browne, President and CEO of Xtant Medical. “By combining enhanced composition, high BMP retention, and versatile handling characteristics, Trivium provides surgeons with a dependable solution for a variety of surgical applications. We are confident that Trivium will deliver consistent, reliable outcomes for patients.”
Trivium represents Xtant Medical’s ongoing commitment to innovation in regenerative medicine, providing surgeons with a high-performance graft that supports optimal outcomes. Trivium is now available to the company’s nationwide distribution network of independent agents.
About Xtant Medical Holdings, Inc.
Xtant Medical’s mission of “honoring the gift of donation so that our patients can live as full and complete a life as possible” is the driving force behind our company. Xtant Medical Holdings, Inc. (www.xtantmedical.com) is a global medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Xtant people are dedicated and talented, operating with the highest integrity to serve our customers.
The symbols ™ and ® denote trademarks and registered trademarks of Xtant Medical Holdings, Inc. or its affiliates, registered as indicated in the United States, and in other countries. All other trademarks and trade names referred to in this release are the property of their respective owners.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or conditions, or that include words such as “intends,” ”expects,” ”anticipates,” ”plans,” ”believes,” ”estimates,” “continue,” “future,” ”will,” “potential,” similar expressions or the negative thereof, and the use of future dates. Forward-looking statements in this release include the Company’s expectations regarding the performance of Trivium and outcomes for patients utilizing Trivium. The Company cautions that its forward-looking statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others: the ability of newly launched products, such as Trivium, to gain market acceptance, perform as designed and intended, and meet the needs of surgeons and patients, including as a result of the lack of robust clinical validation; Xtant’s ability to execute its strategic priorities and become operationally self-sustaining and less reliant on third-party manufacturers and suppliers; its ability to implement successfully future growth initiatives and risks associated therewith; its ability to remain competitive and innovate, develop and introduce new products and the success of those products; its ability to engage and retain new and existing independent distributors and agents and qualified personnel and its dependence on key independent agents for a significant portion of its revenue; the effect of labor and hospital staffing shortages on its business, operating results and financial condition, especially when they affect key markets; the effect of tariffs, inflation, increased interest rates and other recessionary factors and supply chain disruptions; the effect of product sales mix changes on the Company’s financial results; government and third-party coverage and reimbursement for Company products; the ability to obtain and maintain regulatory approvals and comply with government regulations; the effect of product recalls, defects and liability claims and other litigation to which the Company may be subject; the ability to maintain sufficient liquidity to fund its operations and obtain financing on favorable terms or at all; and other factors. Additional risk factors are contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 filed with the Securities and Exchange Commission (SEC) on March 6, 2025 and subsequent SEC filings by the Company. Investors are encouraged to read the Company’s filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The Company undertakes no obligation to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by this cautionary statement.
SOURCE Xtant Medical Holdings, Inc.